Cargando…

Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics

Plenty of evidence has recently shown that various inflammatory activities at the local tissue, organ, or even the whole body (systemic) level are strongly linked to many life-threatening chronic diseases, most notably various cancers. However, only very limited information is available for making g...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wen-Chi, Shyur, Lie-Fen, Yang, Ning-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104968/
https://www.ncbi.nlm.nih.gov/pubmed/35563896
http://dx.doi.org/10.3390/cells11091590
_version_ 1784707924629651456
author Wei, Wen-Chi
Shyur, Lie-Fen
Yang, Ning-Sun
author_facet Wei, Wen-Chi
Shyur, Lie-Fen
Yang, Ning-Sun
author_sort Wei, Wen-Chi
collection PubMed
description Plenty of evidence has recently shown that various inflammatory activities at the local tissue, organ, or even the whole body (systemic) level are strongly linked to many life-threatening chronic diseases, most notably various cancers. However, only very limited information is available for making good use of our supporting immune-modulatory therapeutics for the treatment of cancers. This may result from a lack of studies on specific remedies for efficacious control or modulatory suppression of inflammation-related cancerous diseases. Our group and laboratories were fortunate to have initiated and consistently pursued an integrated team-work program project, aimed at investigating selected medicinal herbs and the derived, purified phytochemical compounds. We focused on the study of key and specific immune-signaling mechanisms at the cellular and molecular levels. We were fortunate to obtain a series of fruitful research results. We believe that our key findings reported herein may be helpful for proposing future thematic and integrated research projects that aim to develop future phytochemical drugs against cancers. The mechanisms of the cellular and molecular systems involved in inflammation are becoming increasingly recognized as keystones for the development of future therapeutic approaches for many chronic and cancerous diseases. Recently, the immune checkpoint inhibitors such as antibodies against PD-1 and/or PD-L1 have been shown to be too expensive for general clinical use, and their effects far from optimal, often showing little or no effect or only short-term efficacy. These results point to the need for developing future immune-regulatory or modulatory therapeutics.
format Online
Article
Text
id pubmed-9104968
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91049682022-05-14 Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics Wei, Wen-Chi Shyur, Lie-Fen Yang, Ning-Sun Cells Commentary Plenty of evidence has recently shown that various inflammatory activities at the local tissue, organ, or even the whole body (systemic) level are strongly linked to many life-threatening chronic diseases, most notably various cancers. However, only very limited information is available for making good use of our supporting immune-modulatory therapeutics for the treatment of cancers. This may result from a lack of studies on specific remedies for efficacious control or modulatory suppression of inflammation-related cancerous diseases. Our group and laboratories were fortunate to have initiated and consistently pursued an integrated team-work program project, aimed at investigating selected medicinal herbs and the derived, purified phytochemical compounds. We focused on the study of key and specific immune-signaling mechanisms at the cellular and molecular levels. We were fortunate to obtain a series of fruitful research results. We believe that our key findings reported herein may be helpful for proposing future thematic and integrated research projects that aim to develop future phytochemical drugs against cancers. The mechanisms of the cellular and molecular systems involved in inflammation are becoming increasingly recognized as keystones for the development of future therapeutic approaches for many chronic and cancerous diseases. Recently, the immune checkpoint inhibitors such as antibodies against PD-1 and/or PD-L1 have been shown to be too expensive for general clinical use, and their effects far from optimal, often showing little or no effect or only short-term efficacy. These results point to the need for developing future immune-regulatory or modulatory therapeutics. MDPI 2022-05-09 /pmc/articles/PMC9104968/ /pubmed/35563896 http://dx.doi.org/10.3390/cells11091590 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Wei, Wen-Chi
Shyur, Lie-Fen
Yang, Ning-Sun
Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title_full Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title_fullStr Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title_full_unstemmed Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title_short Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
title_sort cellular and molecular signaling as targets for cancer vaccine therapeutics
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104968/
https://www.ncbi.nlm.nih.gov/pubmed/35563896
http://dx.doi.org/10.3390/cells11091590
work_keys_str_mv AT weiwenchi cellularandmolecularsignalingastargetsforcancervaccinetherapeutics
AT shyurliefen cellularandmolecularsignalingastargetsforcancervaccinetherapeutics
AT yangningsun cellularandmolecularsignalingastargetsforcancervaccinetherapeutics